Recent findings highlight the potential of nanoparticles in fighting drug-resistant cancer, offering new hope for improving chemotherapy outcomes through advanced treatment methods.
Today's biotech news highlights a lawsuit concerning Duchenne therapy and challenges faced by FDA Commissioner Marty Makary in relation to the White House.
This brief outlines the GENEROUS model and explores various elements that may influence Medicaid drug costs, emphasizing the importance of confidentiality regarding certain model details.
A recent study indicates that lubiprostone, a medication typically used for constipation, may play a role in slowing the progression of chronic kidney disease in patients.
A patient who previously traveled on a cruise ship affected by a hantavirus outbreak has been hospitalized in Zurich after testing positive for the virus. Three more passengers have been evacuated.
Energy Fuels is positioning itself as a key player in the nuclear energy sector with a diverse portfolio that includes uranium, rare earth elements, and medical isotopes.
Researchers from the University of Michigan and MD Anderson Cancer Center have developed a novel nanoparticle therapy that may enhance cancer immunotherapy's safety and efficacy.
Michigan's efforts in radiation emergency preparedness showcase a proactive approach that could serve as a model for health officials nationwide.
A suspected hantavirus outbreak on a Dutch cruise ship has led to the deaths of three passengers, raising alarms about health safety on cruises.
Recent developments suggest that a political appointee may be obstructing the approval process for a Sanofi drug, raising alarms about potential political interference at the FDA.
Sanofi has requested the FDA to withdraw teplizumab from its fast-track review program following internal disagreements regarding the drug's approval.
Following a surprising rejection, the FDA will revisit the treatment for a rare cancer, as the developers of Ebvallo have reached an agreement to tackle the concerns raised.
A recent report indicates a steady increase in hospital shootings since 2000, highlighting a troubling trend in healthcare safety and security.
In a significant move within the pharmaceutical industry, Angelini Pharma has announced its acquisition of Catalyst Pharmaceuticals, a company specializing in treatments for rare diseases, for $4.1 billion.
The commander of Fort Drum has called on state officials to back initiatives in nuclear energy and healthcare, highlighting the importance of these sectors.
The Trump administration's recent actions regarding drug policy appear inconsistent, as the White House endorses treatment methods while imposing new restrictions.
La Trobe scientists have made a pivotal discovery in the fight against dangerous drug-resistant bacteria.
As discussions around pharmaceutical pricing evolve, the 'Most Favored Nation' model emerges as a potential solution worth considering for its implications and benefits.
In a notable move, Sanofi has requested the FDA to withdraw its type 1 diabetes drug from the expedited review process, citing political interference as a key factor.
Color Health is broadening its services to include cancer care coordination, aiming to fill a significant void in the healthcare landscape.